NASD · Healthcare · Biotechnology · USA
Palvella Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing topical therapies for rare skin diseases and vascular malformations with no FDA-approved treatments. The company uses its proprietary QTORIN platform to create product candidates targeting conditions including microcystic lymphatic malformations, cutaneous venous malformations, and disseminated superficial actinic porokeratosis. Its lead candidate, QTORIN rapamycin, is in clinical trials for multiple indications.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Palvella Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on PVLA yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.